Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3
The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
1. A pharmaceutical composition comprising
(i) CHIKV-Δ5nsP3 particles expressing an E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2;
(ii) CHIKV-Δ5nsP3 particles expressing an E2 structural protein having an E168K mutation in the amino acid sequence of SEQ ID NO: 2; and
(iii) optionally a pharmaceutically acceptable excipient,
wherein 1-50% of the CHIKV-Δ5nsP3 particles in the composition express an E2 structural protein having said E168K mutation.
2. A pharmaceutical composition comprising (i) CHIKV-Δ5nsP3 particles; and (ii) optionally a pharmaceutically acceptable excipient; wherein at least 30% of the CHIKV-Δ5nsP3 particles present in the composition express an E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2.
3. The pharmaceutical composition according to claim 1 , wherein at least 50%, at least 75% or at least 90% of the CHIKV-Δ5nsP3 particles present in the composition express the E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2.
4. The pharmaceutical composition according to claim 1 , wherein less than 40%, less than 25% or less than 10% of the CHIKV-Δ5nsP3 particles present in the composition express the E2 structural protein having said E168K mutation.
5. The pharmaceutical composition according to claim 1 , wherein 5-30% or 10-20% of the CHIKV-Δ5nsP3 particles present in the composition express the E2 structural protein having said E168K mutation.
6. The pharmaceutical composition according to claim 1 , which is obtained or obtainable by production of CHIKV-Δ5nsP3 particles in Vero cells.
7. The pharmaceutical composition according claim 1 , wherein said composition induces neutralizing antibodies against CHIKV-Δ5nsP3 in a mouse immunized with said pharmaceutical composition resulting in a serum comprising said neutralizing antibodies and wherein said serum neutralizes Chikungunya virus (CHIKV) infection of Vero cells by at least 80% in an in vitro neutralization assay at a 1:80 serum dilution.
8. The pharmaceutical composition according to claim 1 , wherein said CHIKV-Δ5nsP3 particles in (i) are defined by the polynucleotide sequence of SEQ ID NO: 1.
9. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition comprises an effective amount of CHIKV-Δ5nsP3 particles which express the E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2, wherein said effective amount is defined as at least 10 3 or at least 10 4 CHIKV-Δ5nsP3 particles which express an E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2.
10. The pharmaceutical composition according to claim 9 , wherein said effective amount is defined as about 10 4 CHIKV-Δ5nsP3 particles which express the E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2.
11. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition comprises an effective amount of CHIKV-Δ5nsP3 particles which express the E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2, wherein said effective amount is defined as an amount sufficient to prevent Chikungunya virus viremia in a vaccinated subject.
12. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition is a one-shot pharmaceutical composition.
13. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition is a vaccine.
14. The pharmaceutical composition according to claim 13 , wherein said pharmaceutical composition is provided in a lyophilized form.
15. The pharmaceutical composition according to claim 1 , wherein the composition is formulated for subcutaneous administration.
16. A method of treating or preventing a Chikungunya virus infection in a subject in need thereof, comprising administering an effective amount of the pharmaceutical composition according to claim 1 .
17. A process for producing a pharmaceutical composition comprising CHIKV-Δ5nsP3 particles which express an E2 structural protein as defined by the amino acid sequence of SEQ ID NO: 2 comprising the step of:
growing CHIKV-Δ5nsP3 on host cells in such a way as to minimize the presence of immunogenicity-reducing mutations of the virus.
18. The process according to claim 17 , wherein said CHIKV-Δ5nsP3 particles are defined by a polynucleotide sequence of SEQ ID NO: 1 and are passaged on host cells in culture less than five times.
19. The process according to claim 18 , wherein said CHIKV-Δ5nsP3 particles are passaged on host cells in culture for at most three times.